Genomic Health, Inc., a life science company, engages in the development and commercialization of genomic-based clinical diagnostic tests for cancer that enable physicians and patients to make individualized treatment decisions in the United States. The company's Oncotype DX is a clinical laboratory test, which is used for early stage breast cancer patients to predict the likelihood of cancer recurrence and the likelihood of chemotherapy benefit. It offers Oncotype DX as a clinical laboratory service, where it analyses the expression levels of 21 genes in tumor tissue samples in its laboratory and provide physicians with a quantitative gene expression profile expressed as a single quantitative Recurrence Score. The Oncotype DX report also includes measurements of quantitative gene expression for estrogen receptor (ER) and progesterone receptor (PR), which are used in the calculation of the Recurrence Score result. In addition, the company is in the early development phase to develop tests to predict the likelihood of response to the epidermal growth factor receptor inhibitor class of drugs, as well as for a product to predict the likelihood of taxane benefit in breast cancer patients. Further, it has products in various stages of development for other cancers, including colon cancer, prostate cancer, renal cell cancer, non-small cell lung cancer, and melanoma. The company has collaborative agreements with Aventis, Inc. and the Eastern Cooperative Oncology Group to investigate the ability of gene expression in FPE tissues to predict the likelihood of response to adjuvant chemotherapy, including the taxane Taxotere, in patients with early breast cancer and zero to three involved lymph nodes; and Bristol-Myers Squibb Company and ImClone Systems Incorporated to develop a genomic test to predict the likelihood of response to Erbitux in colorectal cancer. Genomic Health, Inc. was founded in 2000 and is based in Redwood City, California.